Certican 0.25 mg Tablet
10.09$
9.07$
Certican 0.25 mg tablets contain the active ingredient everolimus, an innovative anticancer therapy designed to combat various advanced cancers, including those of the pancreas, stomach, intestines, and lungs, particularly when surgical options are not viable. This medication is particularly effective for postmenopausal women suffering from advanced hormone receptor-positive and HER2-negative breast cancer, offering a targeted approach to treatment. Additionally, Certican is indicated for adult patients with advanced kidney cancer who have not responded to prior therapies such as sunitinib or sorafenib. By inhibiting specific pathways that promote cancer cell growth, everolimus helps slow tumor progression and improve patient outcomes. It's essential to be aware of potential side effects, including increased risk of infection, as this medication can impact immune function. Patients should consult their healthcare provider for thorough guidance and monitoring while using Certican. With its precise mechanism of action, Certican 0.25 mg tablets represent a crucial option in the ongoing fight against complex cancer types.
الكمية
Active Pharmaceutical Ingredient
Uses
• Certican 0 25 mg tablet is utilized in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women. It is often prescribed in combination with exemestane after other treatments, such as letrozole or anastrozole, have failed. The medication helps manage the progression of the disease by targeting specific pathways involved in tumor growth. This approach is critical for patients seeking effective options after prior therapies.
• The application of Certican 0 25 mg tablet extends to the management of neuroendocrine tumors (NETs), which are rare tumors that can develop in various organs, including the lungs and pancreas. By inhibiting certain cellular processes, Certican helps slow the growth of these tumors. Patients diagnosed with NETs may benefit from this treatment as part of their overall management plan. It provides a therapeutic option for those dealing with challenging tumor types.
• In the context of kidney cancer, Certican 0 25 mg tablet is indicated for adult patients who have not responded to treatments like sunitinib or sorafenib. The medication plays a role in controlling tumor growth and improving patient outcomes after other therapies have proven ineffective. By targeting specific molecular pathways, Certican aids in managing the disease more effectively. This is particularly important for patients facing advanced stages of kidney cancer.
• Certican 0 25 mg tablet is also employed in treating renal angiomyolipoma associated with Tuberous Sclerosis Complex (TSC) in adult patients who do not require immediate surgery. This use highlights its role in managing benign tumors that can still pose significant health risks. By controlling the growth of these tumors, Certican contributes to better health outcomes and quality of life for affected individuals. This makes it a valuable part of the treatment landscape for TSC-related conditions.
Benefits
Certican 0.25 mg Tablet is indicated to patients dealing with various cancers such as breast cancer, pancreatic cancer, lung cancer, kidney cancer and stomach/ intestinal cancer. Cancer of this type tends to spread quickly in other parts of the body. Everolimus Tablet 0.25 mg travels through the bloodstream and effectively destroys cancerous cells and other parts of the body. It works by decreasing the activity of the immune system of the body and prevents the rejection of the transplanted organ. Certican 0.25 mg works by stopping the action of an abnormal protein that causes the multiplication of cancerous cells. In this way, it stops the spread of cancerous cells. Besides this, it is also effective in people with genetic disorders to treat some types of tumours in the brain or kidneys.
Side Effects
Certican 0.25 mg Strip may cause some side effects. If you experience any of these side effects contact your doctor as soon as possible. Your doctor may be able to suggest ways to manage or reduce the severity of these side effects.
Most Common Side Effects
• Infection
• Urinary issues
• Hypertension, rise in cholesterol or triglycerides
• Stomach pain, nausea, diarrhoea and/or constipation
• Headache
• Swelling in your legs or feet
Common Side Effects
• Swelling in legs and feet
• Blood in stools and urine
• Burning sensation during urination
• Mouth sores
• Headache
• Tiredness
• Nausea
How To Use
Certican Tablet can be taken by mouth with or without food. Swallow the whole tablet with a glass of water. Do not crush, break, or chew the tablets. Take your dose around the same time every day. It is important to make sure you are taking the correct amount of medication every time. Before every dose, check that what you are taking matches what you have been prescribed. If you miss a dose and it has been less than 6 hours since your regular dose time, take it as soon as you remember. If it has been more than 6 hours, skip the dose. Do not take 2 doses at once to make up for a missed dose.
Safety Advice
• Alcohol: It is generally not recommended to drink alcohol while taking Certican Tablet. It may increase the risk of liver damage. it is best to avoid alcohol or limit your alcohol consumption while taking any medication.
• Kidney: Certican 0.25 mg Tablet is safe to use in patients with kidney disease. No dose adjustment of Certican 0.25 mg is recommended.
• Breastfeeding: It is not recommended to breastfeed while taking Certican 0.25 mg. Immunosuppressant Drug Certican may pass into breast milk and harm the infant. If you are breastfeeding and taking Everolimus Tablet 0.25 mg, it is important to talk to your doctor about the possible risks and benefits of continuing to breastfeed. Your doctor will be able to help you make the best decision for you and your baby's health.
• Liver: Everolimus Tablet 0.25 mg should be used with caution in patients with liver disease. It is important that patients with liver disease closely monitor liver function while taking Certican 0.25 mg and report any unusual symptoms or changes in liver function to their doctor. The dose of Certican 0.25 mg may need to be adjusted in patients with liver disease.
• Pregnancy: Use of Everolimus Tablet 0.25 mg may be unsafe during pregnancy as animal studies indicate that it may harm the developing foetus. However, if you are pregnant or planning to become pregnant, it is important to talk to your doctor about the potential risks and benefits of taking Immunosuppressant Drug Certican during pregnancy. Your doctor will be able to help you make the best decision for you and your baby's health.
• Driving: Certican 0.25 mg Strip may cause dizziness, fatigue, and difficulty concentrating and coordinating, which may affect your ability to drive a vehicle safely. It is important to follow your doctor's instructions and take necessary precautions such as avoiding driving a vehicle or operating heavy machinery if you suffer from the side effects of this Certican 0.25 mg Strip.